ClinicalTrials.gg
Not yet recruitingNCT07864298Updated Oct 7, 2026

Cohesive Bandage Fixation of Pulse Oximeter Probes and Skin Condition in Preterm Neonates

An interventional study of Cohesive bandage fixation of pulse oximeter probe and Standard adhesive fixation of pulse oximeter probe in Skin Injury, Premature Birth and Medical Adhesive Related Skin Injury, sponsored by Uskudar University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 0 Years to 28 Days. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Uskudar University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
0 Years to 28 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Premature Birth with a site in Turkey — 44 open to participants now, 49 under way, none of them phase 3. Premature Birth · Turkey.

Planned enrollment
95th of 197
64 · median 64
Started
2026
with 18 others
No phase
192 of 247
39 open now
Primary completion
2026-11
later than 39 of 48 live
Registered
244th of 247
by date

Among the 247 studies in Premature Birth with a site in Turkey, this one is the 95th largest by planned enrollment of the 197 interventional ones that give a count, is one of 19 that started in 2026, is one of 192 with no phase, reaches primary completion later than 39 of the 48 other live ones, and was the 244th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

44 of the 247 studies in Premature Birth with a site in Turkey are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 0 Years to 28 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Premature Birth with a site in Turkey, or all of them as a file.
02

Study summary

Pulse oximeter probes are used to continuously monitor oxygen levels in newborn babies in intensive care. These probes are usually attached to the baby's hand or foot with adhesive tape and must be moved to a new site every few hours. Repeatedly sticking and removing adhesive can damage the delicate skin of premature babies.

The investigators have developed a new way to secure the probe without any adhesive touching the skin: the probe's adhesive side is attached to a soft, self-adhering (cohesive) bandage that wraps around the baby's hand or foot. The bandage sticks only to itself, not to the skin.

The purpose of this study is to find out whether securing the probe with a cohesive bandage protects the skin better than the standard method of taping the probe directly to the skin. Sixty-four premature babies (born at 32 to 36 weeks) will be randomly placed in one of two groups. In both groups, the probe will be placed on each hand and foot for four hours in turn, for a total of 16 hours. The skin under the probe will be photographed and scored by two nurses who do not know which method was used.

Read the detailed description

Background: The skin of preterm neonates has an immature stratum corneum and a weak dermal-epidermal junction, which makes it vulnerable to epidermal stripping when medical adhesives are removed. The pulse oximeter probe is one of the most frequently applied and repositioned adhesive devices in the neonatal intensive care unit. Probe-related skin injuries, including adhesive-related and pressure-related damage and burns, have been reported. Existing preventive approaches (barrier films, silicone tapes, hydrocolloid dressings) reduce but do not eliminate adhesive contact with the skin. No published randomized controlled trial has tested a fixation method specific to pulse oximeter probes.

Intervention: In the experimental group, a piece of latex-free cohesive bandage (5 cm wide, length 1.5 times the circumference of the application site) is prepared. Two openings matching the probe's light-emitting diode and photodetector windows are cut into the bandage. The probe's original adhesive surface is attached to the bandage, and the free ends of the bandage are wrapped around the extremity so that they adhere only to each other. Alignment of the emitter and detector is verified. Wrap tension is standardized with a capillary refill test (refill within 2 seconds after 5 seconds of pressure proximal to the probe) and the absence of visible skin indentation. In the control group, the probe is applied directly to the skin according to routine practice and manufacturer instructions; the same capillary refill check is performed.

Exposure schedule: In both groups, the probe is rotated across four sites (right foot, left foot, right hand, left hand) at four-hour intervals. Each site carries the probe only once, for a total exposure of 16 hours per infant. A safety check (capillary refill, skin redness, probe displacement) is performed at the second hour of each application.

Outcome assessment: All four sites are photographed before any probe application (baseline). Each site is photographed again 30 minutes after probe removal under standardized conditions (fixed 20 cm distance, ring LED lighting, locked white balance, scale and color reference card in frame). Images are coded, presented in random order, and scored independently by two observers blinded to group allocation using the Neonatal Skin Condition Score adapted to the probe site.

Randomization: A computer-generated block randomization list with variable block sizes (4 and 6) is prepared by an independent statistician. Allocations are concealed in sequentially numbered, opaque, sealed envelopes.

Pilot phase: Before the main study, 8 to 10 neonates will be included in a pilot phase to test the adapted scoring form, photography setup and interobserver agreement, and to compare oxygen saturation readings between cohesive bandage and standard adhesive fixation (Bland-Altman analysis). Pilot data will not be included in the main analysis.

Statistical analysis: The unit of analysis is the application site. Because the four sites of each infant are not independent, a linear mixed-effects model will be used, with infant as a random effect and group, baseline score and site (hand/foot) as fixed effects. Analysis will follow the intention-to-treat principle, with a per-protocol sensitivity analysis.

03

Conditions studied

  • Skin Injury
  • Premature Birth
  • Medical Adhesive Related Skin Injury

Keywords

  • newborn
  • Pulse Oximetry
  • Cohesive Bandage
  • Skin Condition
  • Nursing Care
  • Neonatal Intensive Care Unit
  • Neonatal Skin Condition Score
04

Who can participate

Ages eligible
0 Years to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age 32 0/7 to 36 6/7 weeks
  • Birth weight 1500 g or more
  • Requiring continuous pulse oximetry monitoring, expected to last at least 16 hours
  • No primary skin lesion, congenital anomaly or active dermatological disease
  • Written from a parent

Exclusion criteria

Exclusion Criteria:

  • Hydrops fetalis or generalized peripheral edema
  • Systemic , or vasoactive drug use
  • Impaired peripheral circulation in the extremities to be used for probe application
  • Skin changes due to uremia or cholestasis
  • Receiving phototherapy or topical pharmacological application to the skin
  • Receiving sedation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Cohesive Bandage Fixation

    The pulse oximeter probe is attached to a cohesive bandage wrapped around the extremity, with no adhesive contact with the skin. The probe is rotated across four extremities at four-hour intervals (16 hours in total).

    Other: Cohesive bandage fixation of pulse oximeter probe

  • Active comparator
    Standard Adhesive Fixation

    The pulse oximeter probe is applied directly to the skin with its own adhesive according to routine practice and manufacturer instructions. The probe is rotated across four extremities at four-hour intervals (16 hours in total).

    Other: Standard adhesive fixation of pulse oximeter probe

Interventions

  • OtherCohesive bandage fixation of pulse oximeter probe

    The adhesive surface of the pulse oximeter probe is attached to a latex-free cohesive bandage (5 cm wide, length 1.5 times the circumference of the site) with openings matching the emitter and detector windows. The bandage ends adhere only to each other, so no adhesive contacts the skin. Wrap tension is checked with a capillary refill test.

  • OtherStandard adhesive fixation of pulse oximeter probe

    The pulse oximeter probe is applied directly to the skin with its original adhesive according to routine practice and manufacturer instructions.

06

What researchers measure

Primary outcomes

  1. Neonatal Skin Condition Score (NSCS) total score at the probe application site

    Skin condition at each probe application site is assessed with the Neonatal Skin Condition Score adapted to the probe site. The score includes three items (dryness, erythema, skin breakdown), each scored from 1 to 3; the total score ranges from 3 (best) to 9 (worst). Scoring is performed on standardized photographs by two independent observers blinded to group allocation, and the mean of the two observers' scores is used.

    Time frame: 30 minutes after probe removal at the end of each 4-hour application (up to 16 hours)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to the small sample size of neonatal participants and the need to protect patient confidentiality, including standardized skin photographs. Aggregated results will be reported in publications.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Nov 2026, 1 month later.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 1 month is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartEst.
Oct 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864298
Lead sponsor
Uskudar University
Responsible party
Tugba KARAKUS TURKER (Assistant Professor, Uskudar University) — Principal investigator
First posted
Oct 7, 2026
Start date
Oct 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 7, 2026

Study contacts

Tuğba Karakuş Türker, PhD
Contact
tugba.karakusturker@uskudar.edu.tr
+905439599371

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion